NCT04034316View on ClinicalTrials.gov

Reduce Immunosuppression With Atmp in NS ChildrEn

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 2, 2018

Primary Completion Date

March 31, 2023

Study Completion Date

August 31, 2023

Conditions
Nephrotic Syndrome in ChildrenSteroid-Dependent Nephrotic SyndromeIdiopathic Nephrotic Syndrome
Interventions
OTHER

Cord-blood mesenchymal stromal cells

The product is packaged in bags suitable for the cryopreservation of cell products. Before administration the cells must be thawed and diluted in an appropriate vol:vol solution: made by saline 78%, human albumin 10%, Acyl-CoA dehydrogenase-A (ACD-A) 12%.

Trial Locations (1)

Unknown

Pediatric Nephrology, Dialysis and Transplant Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan, Milan

All Listed Sponsors
collaborator

Cell Factory Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

UNKNOWN

collaborator

Laboratorio Sperimentale di Immunologia e Trapianti, Oncoematologia Pediatrica, Fondazione IRCCS Policlinico S. Matteo, Pavia

UNKNOWN

lead

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

OTHER

NCT04034316 - Reduce Immunosuppression With Atmp in NS ChildrEn | Biotech Hunter | Biotech Hunter